Australia markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.1800-0.0100 (-0.46%)
At close: 04:00PM EDT
2.0500 -0.13 (-5.96%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1900
Open2.2000
Bid2.1600 x 300
Ask2.1900 x 100
Day's range2.1700 - 2.3000
52-week range1.0400 - 2.8550
Volume2,853,490
Avg. volume917,229
Market cap147.633M
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.90
  • GlobeNewswire

    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors. “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. “With his ext

  • GlobeNewswire

    CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

    - Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - CytomX retains option for US co-commercialization and economic rights for certain programs - SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of condi

  • Simply Wall St.

    CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

    CytomX Therapeutics ( NASDAQ:CTMX ) Full Year 2023 Results Key Financial Results Revenue: US$101.2m (up 90% from FY...